Skip to main content

Recent Research

AKINESIS  -  Sponsored by Abbott/Alere

AKINESIS is a clinical study to assess the utility of blood and urine NGAL tests in predicting worsening kidney function in patients who present with acute heart failure (AHF) and who are treated with diuretics. It is believed that rising NGAL levels in the blood and/or urine can predict acute kidney injury. It is also believed that patients who are admitted to the hospital with high NGAL levels in the blood/urine will have poorer outcomes.


CAMEO  -  Sponsored by Shire Orphan Therapies, Inc.

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety and Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults


CAPTURE  -  Sponsored by Cerexa

To compare the time to pathogen eradication, and the relationship to the time to clinical improvement, between ceftaroline and case-matched vancomycin treated controls in the treatment of adults with serious infections caused by Methicillin-Resistant Staphylococcus aureus (MRSA).


CroFab  -  Sponsored by BTG International Inc.

A Randomized, Double-Blind, Placebo-Controlled Study Comparing CroFab® Versus Placebo With Rescue Treatment for Copperhead Snake Envenomation


The DISCOVER Registry  -  Sponsored by Cubist Pharmaceuticals Inc.

A multicenter, prospective, observational study of clinical and economic outcomes in patients treated with fidaxomicin for Clostridium difficile-associated diarrhea (CDAD)


MARINER  -  Sponsored by Janssen Research & Development, LLC

The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in high-risk, medically ill patients.


SAFER: Shock Access For Emergent Resuscitation - Sponsored by Vidacare, LLC

The primary objective of SAFER is to describe the process of initial vascular access device (VAD) placement and parenteral fluid challenge within the first 1 hour following ED arrival in hypotensive non‐traumatic emergency department patients. SAFER is an observational, descriptive, prospective multi‐center study of hypotensive non‐traumatic patients requiring ≥ 1 liter bolus of parenteral fluid administration within the first 1 hour following ED arrival.


TRUE-AHF  -  Sponsored by Cardiorentis

Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering From Acute Decompensated Heart Failure


Investigator Initiated Studies


PCP-UDS

Identification of Synthetic Cathinones and Phencyclidine Analogues in Phencyclidine-Positive Urine Drug Screens

Predicting Mortality Using Serum Lactate Levels and Age

This is a retrospective cohort study of the hospital discharge database of ED patients > 18 years of age from May 1, 2009 to May 31, 2013 at an urban, tertiary care teaching hospital emergency department that had a lactate level obtained during the course of their care in the ED. Age, sex, race, vital signs, comorbidities, and diagnoses will be obtained from the hospital discharge database.

  • Principal InvestigatorChad Cannon, MD
  • Sub Investigator:  Seth Purcell, MD
Last modified: Sep 28, 2018
ID=x23511